Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.

In multiple logistic regression analysis, only anti-dsDNA positivity was associated with the outcome, yielding a nearly 2-fold increased probability of achieving cSLEDAI-2K = 0 along with a prednisone (or prednisone equivalent) dose of ⩽7.5 mg/day (OR: 1.74; 95% CI 1.03, 2.94; P = 0.040), whereas the association between baseline SDI scores of > 0 and failure to achieve clinical remission with the CS restriction did not reach statistical significance (OR: 0.63; 95% CI 0.40, 1.02; P = 0.06).

also in 111,027 other papers